Aragen Bioscience Announces Ground Breaking on State Of the Art Research Facility
News Jan 29, 2016
Dedicated to the testing and characterization of novel therapeutics and vaccines, the new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies. Such studies are critical to the development of products that improve the diagnosis, treatment and prevention of disease including for example, fibrotic and infectious disease, oncology and other immunologically related indications.
“This project demonstrates Aragen’s commitment to future growth and meeting the needs of our clients for value-added services. The new facility not only expands general capacity but is constructed for high technical performance and tight environmental control including provision of BSL-2 studies. We look forward to seeing the building progress and its opening later this year,” commented Dr. Malavika Ghosh, Aragen’s Vice President of Preclinical Services.
The facility, which is designed for AAALAC accreditation and GLP compliance, is scheduled to be functional in the second quarter of 2016.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE